中国金茂(00817.HK)完成配股及认购新股份筹资8.15亿港元
格隆汇8月6日丨中国金茂(00817.HK)发布公告,配售事项及认购事项所有条件均已达成,配售事项及认购事项分别已于2019年8月2日及2019年8月6日完成。根据平安协议及新华协议条款及条件,卖方以每股4.8106港元的价格分别向投资管理人(为平安正式委任投资管理人)及新华出售约17.87亿股及1555.99万股股份,而公司于2019年8月6日以每股4.8106港元的价格向卖方配发及发行合共约1.69亿股股份(占经认购事项扩大后公司已发行股本约1.44%)。认购事项所得款项净额约为8.15亿港元,将用作集团的一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.